EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics

Clelia Madeddu iD, Eleonora Lai iD, Manuela Neri, Elisabetta Sanna, Giulia Gramignano, Sonia Nemolato iD, Mario Scartozzi iD, Sabrina Giglio, Antonio Macciò iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26052232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Clelia Madeddu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, Department of Medical Sciences and Public Health, University Hospital Cagliari, University of Cagliari, 09100 Cagliari, Italy. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Ovarian Neoplasms, Mutation, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The integrity of p53 machinery is crucial for platinum activity, while p53 mutation is frequent in high-grade serous ovarian cancer (HGS-OC). This study aimed to evaluate the link between p53 mutations, platinum sensitivity (PS), and the platinum-free interval (PFI) in patients with HGS-OC. We prospectively analyzed 159 consecutive women with ovarian cancer who underwent surgery. The somatic mutational status of BRCA, HRD, and TP53 (according to structural, hotspot, and functional classification) was evaluated. Among enrolled patients, 82.4% of cases were TP53-mutated (MT), and 27.8% were BRCA-MT. The distribution of TP53 mutation categories did not differ significantly between the BRCA-MT and wild-type (WT) cases. In the entire population, the proportion of PS patients was significantly lower in TP53-MT compared to TP53-WT (p = 0.0208), in nonsense/frameshift/splicing compared to missense (p = 0.0319), and in loss-of-function (LOF) compared to GOF (p = 0.0048) MT cases. For the BRCA-MT patients, structural and functional TP53 mutations were not significantly different between the PS and PR patients. Conversely, for the BRCA WT patients, the distribution of structural and functional TP53 mutations significantly differed between PS and PR patients. In a multivariate regression analysis, LOF mutations were found to be independent negative predictors of PS (HR: 0.1717; 95% CI: 0.0661–0.4461; p-value: 0.0003). Kaplan–Meier curves showed a significantly lower PFI in cases with LOF mutations in the overall population (log-rank p = 0.0020) and in BRCA-WT patients (log-rank p = 0.0140). Via multivariate COX testing, it was found that LOF mutations were independently associated with a decreased PFI (p = 0.0036). In conclusion, our data show that HGS-OC harboring p53 LOF mutations is the poorest prognostic subgroup regarding PS and the PFI. Further studies are needed to confirm our findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53Ovarian NeoplasmsMutationDrug Resistance, NeoplasmCystadenocarcinoma, SerousPlatinumHumansFemaleMiddle AgedAgedPrecision MedicineAdultNeoplasm GradingAged, 80 and overProspective StudiesAntineoplastic Agents

Stichwörter der Autor:innen

BRCA mutationsPARP inhibitorscisplatinovarian cancerp53 mutationplatinum sensitivity

Substanzen

Tumor Suppressor Protein p53TP53 protein, humanPlatinumAntineoplastic Agents

Autor:innen und Institutionen

  • Medical Oncology Unit, Department of Medical Sciences and Public Health, University Hospital Cagliari, University of Cagliari, 09100 Cagliari, Italy.
  • Gynecologic Oncology Unit, ARNAS G. Brotzu, Department of Surgical Sciences, University of Cagliari, 09100 Cagliari, Italy.
  • Medical Oncology Unit, San Gavino Hospital, 09037 San Gavino, Italy.
  • Department of Pathology, ARNAS G. Brotzu, 09100 Cagliari, Italy.
  • Medical Genetics Unit, Department of Medical Sciences and Public Health, R. Binaghi Hospital, University of Cagliari, ASL 8, 09100 Cagliari, Italy.

ORCID-Profile: Clelia Madeddu, Eleonora Lai, Sonia Nemolato, Mario Scartozzi, Antonio Macciò

Zitieren

APA

Madeddu, C., Lai, E., Neri, M., Sanna, E., Gramignano, G., Nemolato, S., Scartozzi, M., Giglio, S., & Macciò, A. (2025). Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052232

Vancouver

Madeddu C, Lai E, Neri M, Sanna E, Gramignano G, Nemolato S, et al. Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052232

BibTeX
@article{Madeddu2025,
  author = {Madeddu, Clelia and Lai, Eleonora and Neri, Manuela and Sanna, Elisabetta and Gramignano, Giulia and Nemolato, Sonia and Scartozzi, Mario and Giglio, Sabrina and Macciò, Antonio},
  title = {Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26052232}
}
Kostenlos starten →